New York, New York, United States, November 19, 2026
AstraZeneca has entered into a strategic collaboration with the Lupus Research Alliance (LRA) and its clinical research affiliate, Lupus Therapeutics (LT), to advance patient-centred research and accelerate the development of potential treatments for lupus. Announced on November 19, 2026, the partnership will combine the research expertise of the Lupus Research Alliance, the clinical trial capabilities of the Lupus Clinical Investigators Network (LuCIN) and the pharmaceutical development experience of AstraZeneca. The collaboration aims to strengthen patient engagement, improve clinical trial awareness, support recruitment and expand participation across the company’s lupus development programmes. By bringing together researchers, healthcare professionals, clinical investigators and people living with lupus, the partners intend to improve the design and execution of clinical studies. The initiative will cover multiple stages of drug development, from early clinical research to the evaluation of potential therapies in patients. This integrated approach is particularly important for lupus, a complex autoimmune disease with diverse clinical manifestations and treatment needs. The partnership is expected to support the development of more representative clinical studies and help address challenges associated with patient recruitment and retention.
Collaboration Strengthens Lupus Clinical Trial Recruitment
A major component of the collaboration is the involvement of Lupus Therapeutics and its Lupus Clinical Investigators Network, which connects clinical research sites and investigators involved in lupus studies. The network will work with AstraZeneca to support study conduct, clinical trial awareness, patient education and recruitment activities. The collaboration will also include peer-to-peer support and early education, helping patients understand clinical research opportunities and make informed decisions about participation. Education initiatives will extend to healthcare professionals and patients, with an emphasis on improving awareness of ongoing studies and the importance of clinical research. A key objective is to strengthen patient-centred trial design by incorporating the experiences and perspectives of people living with lupus. This approach may help researchers address practical barriers to participation, improve communication between study teams and patients, and support broader representation across clinical programmes. The partnership will initially support several AstraZeneca research initiatives, including the paediatric clinical trial of anifrolumab-fnia, known as BLOSSOM. The programme will also extend to investigational therapies being evaluated in systemic lupus erythematosus (SLE) and lupus nephritis (LN). By combining a dedicated clinical network with patient engagement resources, the collaboration seeks to create a more coordinated environment for lupus drug development.
Anifrolumab and Emerging Cell-Based Therapies Included
The collaboration will support clinical research involving anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, in the paediatric BLOSSOM trial. Type I interferons play an important role in immune-system signalling and are associated with inflammatory activity in lupus. Anifrolumab targets this pathway and is an established treatment option for eligible adults with certain forms of systemic lupus erythematosus. The partnership also covers several investigational approaches in early clinical development, including AstraZeneca’s CD19/BCMA-targeted CAR-T cell therapy and two T-cell engager programmes. The first, TITAN, is investigating a CD8-guided CD20 T-cell engager, while ASSURO is evaluating a bispecific CD19 T-cell engager. These approaches represent emerging strategies designed to target specific immune-cell populations involved in autoimmune disease. CAR-T therapies use genetically engineered T cells to recognise selected targets, while T-cell engagers are designed to bring immune cells into close contact with target cells to promote targeted immune activity. Their investigation in lupus reflects growing interest in approaches that may potentially achieve deeper and more sustained immune modulation. The programmes remain under clinical development, and additional research will be needed to establish their safety, efficacy and long-term benefits in people with lupus.
Longstanding Research Partnership Supports Future Innovation
The new collaboration builds on a longstanding relationship between the Lupus Research Alliance and AstraZeneca. Earlier research funded by the LRA helped identify a distinct set of genes activated by type I interferons in people with lupus, contributing to scientific understanding of the role of interferon signalling in the disease. AstraZeneca subsequently advanced the development of anifrolumab, demonstrating how foundational research can contribute to the development of new treatment options. The organisations now aim to extend this collaborative model across a broader range of investigational therapies and clinical programmes. Lupus is a chronic autoimmune disease in which the immune system produces autoantibodies that mistakenly target the body’s own tissues and organs. It can affect the kidneys, brain, heart, lungs, skin, joints and blood, with symptoms and disease severity varying considerably among patients. The disease predominantly affects women and is frequently diagnosed between the ages of 15 and 45. Through this partnership, the organisations aim to strengthen the connection between scientific discovery, clinical development and patient involvement. Improved clinical trial participation, patient education and more inclusive research programmes could help support the development of future lupus treatments. The collaboration represents an important step towards a more coordinated and patient-focused approach to autoimmune disease research.
Source: AstraZeneca, Lupus Research Alliance press release



